Dr. Yang has spent over 15 years focused on the development of immuno-oncology agents. He is currently development lead for melanoma/genitourinary (GU) cancer at Bristol-Myers Squibb Company (BMS), responsible for the vision and growth strategy for GU cancer drug development including renal cell carcinoma, bladder and prostate cancers. He joined BMS in 2010 with prior roles including early asset oncology development lead and Nivolumab-Ipilimumab life cycle management medical lead.
Dr. Yang received his M.D. and Ph.D. in tumor immunology from the University of Medicine and Dentistry of New Jersey. He completed his residency in internal medicine at Beth Israel Deaconess Medical Center followed by a medical oncology fellowship at Memorial Sloan Kettering Cancer Center.